ANALYSIS OF DASATINIB AND IMATINIB 5-YEAR EFFICACY AND SAFETY BASED ON BASELINE COMORBIDITY AND AGE IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) IN DASISION

被引：0
|
作者：
Saglio, G. [1 ]
Cortes, J. E. [2 ]
Hochhaus, A. [3 ]
Shah, N. P. [4 ]
Atallah, E. L. [5 ,6 ]
Abaskharoun, M. [7 ]
Li, L. [7 ]
Mauro, M. J. [8 ]
机构：
[1] Univ Turin, Turin, Italy
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Univ Klinikum Jena, Jena, Germany
[4] Univ Calif San Francisco, Sch Med, San Francisco, CA USA
[5] Froedtert, Milwaukee, WI USA
[6] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[7] Bristol Myers Squibb Co, Princeton, NJ USA
[8] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
HAEMATOLOGICA | 2017年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
E1060
引用
收藏
页码：436 / 437
页数：2
相关论文
共 50 条
  • [1] Efficacy and Safety Outcomes by Baseline Comorbidity and Age in Patients Newly Diagnosed with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Treated with Dasatinib or Imatinib in DASISION
    Mauro, Michael J.
    Cortes, Jorge E.
    Hochhaus, Andreas
    Shah, Neil P.
    Atallah, Ehab
    Abaskharoun, Mena
    Sy, Oumar
    Saglio, Giuseppe
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (10): : S14 - S15
  • [2] Five-Year Efficacy and Safety of Dasatinib and Imatinib by Baseline Comorbidity and Age in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) from DASISION
    Mauro, Michael J.
    Cortes, Jorge E.
    Hochhaus, Andreas
    Shah, Neil P.
    Atallah, Ehab L.
    Abaskharoun, Mena
    Sy, Oumar
    Saglio, Giuseppe
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S312 - S313
  • [3] 5-YEAR EFFICACY OF DASATINIB AND IMATINIB IN NEWLY DIAGNOSED PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) WITH DOSE MODIFICATIONS FROM DASISION
    Hochhaus, A.
    Jabbour, E.
    Kantarjian, H.
    Guilhot, F.
    Kota, V.
    Hughes, T. P.
    Shelat, S.
    Li, L.
    Cortes, J. E.
    HAEMATOLOGICA, 2017, 102 : 433 - 433
  • [4] Effect of Dose Modifications on 5-Year Efficacy of Dasatinib and Imatinib in Newly Diagnosed Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) From DASISION
    Cortes, Jorge E.
    Hochhaus, Andreas
    Kantarjian, Hagop
    Guilhot, Francois
    Kota, Vamsi
    Hughes, Timothy P.
    Shelat, Suresh
    Sy, Oumar
    Jabbour, Elias
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S308 - S309
  • [5] Safety and Efficacy of Dasatinib Versus Imatinib by Baseline Cardiovascular Comorbidity In Patients with Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Analysis of the DASISION Trial.
    Saglio, Giuseppe
    Hochhaus, Andreas
    Cortes, Jorge E.
    Kantarjian, Hagop
    Baccarani, Michele
    Bradley-Garelik, M. Brigid
    Dejardin, David
    Shah, Neil P.
    BLOOD, 2010, 116 (21) : 942 - 942
  • [6] Dasatinib (Versus Imatinib) In Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Analysis of Safety and Efficacy by Use of Baseline Medications In the DASISION Trial.
    Guilhot, Francois
    Kantarjian, Hagop
    Shah, Neil P.
    Hochhaus, Andreas
    Bradley-Garelik, M. Brigid
    Dejardin, David
    Cortes, Jorge E.
    BLOOD, 2010, 116 (21) : 946 - 947
  • [7] Safety and Efficacy of Dasatinib (DAS) Vs. Imatinib (IM) by Baseline Comorbidity In Patients with Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Analysis of the DASISION Trial
    Khoury, H. Jean
    Cortes, Jurge E.
    Kantarjian, Hagop
    Baccarani, Michele
    Shah, Neil P.
    Bradley-Garelik, M. Brigid
    Dejardin, David
    Hochhaus, Andreas
    BLOOD, 2010, 116 (21) : 1401 - 1401
  • [8] EFFICACY AND SAFETY OF DASATINIB VS IMATINIB IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): EUROPEAN SUBPOPULATION ANALYSIS OF THE PHASE 3 DASISION TRIAL
    Mayer, J.
    Warzocha, K.
    Huguet, F.
    Stegelmann, F.
    Steegmann, J.
    Gambacorti-Passerini, C.
    Lofgren, C.
    Dejardin, D.
    Hochhaus, A.
    HAEMATOLOGICA, 2012, 97 : 75 - 75
  • [9] Dasatinib vs imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): DASISION European subpopulation analysis
    Stegelmann, F.
    Mayer, J.
    Warzocha, K.
    Huguet, F.
    Steegmann, J. L.
    Gambacorti-Passerini, C.
    Lofgren, C.
    Dejardin, D.
    Hochhaus, A.
    ONKOLOGIE, 2012, 35 : 47 - 48
  • [10] Long-term 5-year results of the phase 3 DASISION trial (dasatinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase [CML-CP])
    Stegelmann, F.
    Cortes, J.
    Saglio, G.
    Baccarani, M.
    Kantarjian, H.
    Mayeri, J.
    Bogue, C.
    Shah, N. P.
    Chuah, C.
    Casanova, L.
    Narayanan, G.
    Bradley-Garelik, B.
    Manos, G.
    Hochhaus, A.
    Oncology Research and Treatment, 2015, 38 : 23 - 24
12345